ストックスクリーナーアプリを入手
1.43
2.14%
0.03
前日終値:
$1.40
開ける：
$1.43
24時間の取引高:
76,175
Relative Volume:
0.06
時価総額：
$126.23M
収益：
-
当期純損益:
$-22.83M
株価収益率:
-1.8101
EPS:
-0.79
ネットキャッシュフロー:
$-20.87M
1週間 パフォーマンス:
-2.05%
1か月 パフォーマンス:
-6.54%
6か月 パフォーマンス:
+376.67%
1年 パフォーマンス:
+120.68%
1日の値動き範囲:
$1.4001
$1.45
1週間の範囲:
$1.3701
$1.62
52週間の値動き範囲:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
名前
Cognition Therapeutics Inc
セクター
電話
412-481-2210
住所
2500 WESTCHESTER AVE, PURCHASE
CGTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.43 | 123.58M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.95 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
789.42 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.95 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
853.80 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.33 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 開始されました | B. Riley Securities | Buy |
| 2021-11-03 | 開始されました | Oppenheimer | Outperform |
Cognition Therapeutics Inc (CGTX) 最新ニュース
Earnings Risk: Why Cognition Therapeutics Inc stock could outperform in 2025Earnings Summary Report & Community Consensus Stock Picks - moha.gov.vn
How Cognition Therapeutics Inc. stock reacts to oil prices2025 Earnings Impact & Daily Technical Stock Forecast Reports - Улправда
Why Cognition Therapeutics Inc. stock could outperform in 20252025 Trading Recap & Daily Oversold Stock Bounce Ideas - bolumsonucanavari.com
[8-K] COGNITION THERAPEUTICS INC Reports Material Event | CGTX SEC FilingForm 8-K - Stock Titan
Cognition Therapeutics Launches New $75M ATM Offering - TipRanks
Growth Value: How Cognition Therapeutics Inc. stock reacts to oil prices2025 Short Interest & Daily Profit Maximizing Tips - Улправда
[S-3] COGNITION THERAPEUTICS INC Shelf Registration Statement | CGTX SEC FilingForm S-3 - Stock Titan
Cognition Therapeutics launches new $75M ATM offering - MSN
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Yahoo Finance
Cognition Therapeutics (NASDAQ:CGTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Why retail investors pile into Cognition Therapeutics Inc. stock2025 Growth vs Value & Daily Momentum Trading Reports - Newser
HC Wainwright & Co. Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
CGTX Analyst Rating: HC Wainwright & Co. Maintains Buy Rating | - GuruFocus
Why Cognition Therapeutics Inc. stock is favored by pension fundsJuly 2025 Closing Moves & Free High Return Stock Watch Alerts - Newser
Cognition Therapeutics completes enrollment in expanded access program By Investing.com - Investing.com Nigeria
Cognition Therapeutics completes enrollment in expanded access program - Investing.com India
Cognition Therapeutics Says Zervimesine Expanded Access Program Reaches Full Enrollment - marketscreener.com
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Yahoo Finance
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga
Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s - MSN
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug By Investing.com - Investing.com Nigeria
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug - Investing.com
Cognition Therapeutics outlines phase 3 Alzheimer's plan at CTAD - marketscreener.com
Cognition Therapeutics Outlines Phase 3 Alzheimer's Plan at CTAD - TradingView
Cognition Therapeutics, Inc. Plans to Align with EMA on Alzheimer's Disease Strategy for Zervimesine at February 2026 Meeting - Quiver Quantitative
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference - marketscreener.com
Cognition Therapeutics (NASDAQ: CGTX) maps Phase 3 AD trial after 95% decline slowdown - Stock Titan
Cognition Therapeutics Inc Stock Analysis and ForecastConsumer Goods Stocks & Affordable Market Investment - earlytimes.in
Cognition Therapeutics Inc. (CGTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Q1 Earnings Forecast for CGTX Issued By B. Riley - MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics: A High-Stakes Bet On A Single DrugWhy I Hold (NASDAQ:CGTX) - Seeking Alpha
B. Riley Securities Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
Cognition Therapeutics (CGTX) Sees Analyst Price Target Boost | CGTX Stock News - GuruFocus
B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating - marketscreener.com
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - The Manila Times
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Speak at Annual Piper Sandler Healthcare Conference - Quiver Quantitative
Cognition Therapeutics (Nasdaq: CGTX) CEO Talk at 37th Piper Sandler Healthcare Conf - Stock Titan
Will Cognition Therapeutics Inc. stock beat EPS estimatesJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Can Cognition Therapeutics Inc. stock beat analyst upgradesEarnings Trend Report & AI Enhanced Trading Alerts - newser.com
What analyst consensus says on Cognition Therapeutics Inc. stock - newser.com
Will Cognition Therapeutics Inc. stock pay special dividendsPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
CGTX: HC Wainwright Reiterates Buy Rating and Price Target | CGT - GuruFocus
How to use a screener to detect Cognition Therapeutics Inc. breakoutsTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Why Cognition Therapeutics Inc. stock appeals to dividend seekersIndex Update & Long-Term Growth Plans - newser.com
Cognition Therapeutics Inc (CGTX) 財務データ
収益
当期純利益
現金流量
EPS
0.28%
0.98%
大文字化:
|
ボリューム (24 時間):